Four human astrocytic gliomas of high grade of malignancy were each evaluated in tissue and in vitro for percentages of cells expressing glial fibrillary acidic protein (GFAP), collagen type IV, laminin and fibronectin assessed by immunofluorescence with counterstaining of nuclear DNA. Percentages of cells with reticulin and cells binding fluorescein-labeled Ulex europaeus agglutinin were also assessed. In tissue, each extracellular matrix (ECM) component was associated with cells in the walls of abnormal proliferations of glioma vessels, and all four tumors had the same staining pattern. Two strikingly different patterns of conversion of gene product expression emerged during in vitro cultivation. (1). In the most common pattern, percentages of all six markers consistently shifted toward the exact phenotype of mesenchymal cells in abnormal vascular proliferations: increased reticulin, collagen type IV, laminin and fibronectin; markedly decreased glial marker GFAP and absent endothelial marker Ulex europaeus agglutinin. The simplest explanation of this constellation of changes coordinated toward expression of vascular ECM markers is that primary glioma cell cultures are overgrown by mesenchymal cells from the abnormal vascular proliferations of the original glioma. These cell cultures were tested for in situ hybridization (ISH) signals of chromosomes 7 and 10. Cells from one glioma had diploid signals. Cells from the other glioma had aneuploid signals indicating they were neoplastic; however, their signals reflected different numerical chromosomal aberrations than those common to neoplastic glia. (2). The second pattern was different. Cells with ISH chromosomal signals of neoplastic glia retained GFAP, and gained collagen type IV. Their laminin and fibronectin diminished, but persisted among a lower percentage of cells. Cloning and double immunofluorescence confirmed the presence of individual cells with glial and mesenchymal markers. A cell expressing GFAP in addition to either fibronectin, reticulin or collagen type IV is not a known constituent of glioblastoma tissue. This provides evidence of a second mechanism of conversion of gene expression in gliomas.
Introduction
The capacity of malignant astrocytic gliomas to elaborate and modify their extracellular matrix (ECM) is a fundamental property which may be directly relevant to glial-stromal interactions related to tumor cell infiltration and tumor angiogenesis. A distinct aspect of glioma cells is their ability to change their expression of their ECM and glial gene products [1] [2] [3] . As gliomas progress from low to high grade of malignancy in situ, ECM associated with vascular and mesenchymal components increases in structures commonly called endothelial proliferations [3] [4] [5] [6] [7] [8] [9] . The glial product GFAP often is reduced with increased grade [10] . One of the most malignant gliomas, the gliosarcoma contains an increased mesenchymal component which is clearly malignant in certain patients [11] [12] [13] . These progressions have been called 'mesenchymal drift'. Cultivation of gliomas in vitro accelerates similar changes in the mesenchymal ECM constituent, fibronectin, and in GFAP [14] [15] [16] [17] [18] . A better understanding of the mechanisms that cause mesenchymal drift could provide insight into these fundamental properties of malignant astrocytic gliomas.
Two different mechanisms that would explain mesenchymal drift are: 1) a single cell type with highly variable expression of these gene products [19] [20] [21] and 2) two different types of cells, one of which outgrows the other [17, 18, [21] [22] [23] . A difference between these two possibilities is a constraint imposed by the second mechanism upon the direction of changes in antigenic phenotype. If a cell type overgrows another cell type, the resulting phenotypic changes should maintain a lineage-consistent direction. That is, if the overgrowing cell type is a cell of specific lineage within the original glioma tissue, the changes should reflect an alteration toward the phenotype of this lineage.
In contrast, the first mechanism of variable gene product expression would not necessarily produce such a consistent change in the pattern of the phenotype. Bi-lineal, rather than mono-lineal, alterations might be possible. There is little quantitative information about alterations in expression of a group of gene products that cross major cell lineage boundaries. However, cloning of a single human glioma cell line has shown bi-directional alterations in expression of a group of neuroectodermal markers [20] .
The present study was designed to test the question whether changes occur in a group of ECM components and cell lineage markers between tissue and early primary culture in vitro of human gliomas. If so, would the pattern of changes provide clues regarding the mechanism underlying these changes?
Materials and methods

Glioma tissues
The gliomas used in this study were graded by the neuropathologist (PEM) using criteria of the World Health Organization [5, 24] . Tissue samples for cell culture and cryostat sectioning were taken from the same fresh 0.05-0.2 cm 3 fragment of glioma tissue bisected under sterile conditions. One half was minced for culture and the other half was mounted on a cryostat chuck, sectioned at 7 microns and fixed for 10 rain in 100% methanol [4] . Starting material was limited by the need for adequate diagnostic material on these primary biopsies. Autopsy samples of human skin and brain tissue were controls.
Cell cultures
Standard techniques were used for glioma cell culture as described previously [16, 25] . Primary glioma cell cultures were used as early as possible within experimental requirements for duplicate samples grown in special media for six different marker studies. The average passage available was passage four.
Three established human glioma cell lines and cultured fibroblasts were controls. One line (LM) was an established human glioma line from frozen stock in passage 165. The LM line has been characterized previously [26, 27] . The extensively characterized U138 MG human glioma [16, 28] was obtained from the American Type Culture Collection, Rockville, MD. The GFAP+ U251MG human glioma line was obtained as frozen stock in passage 305 [29] . Human fibroblasts were cultured from skin taken at circumcision or at skin biopsy.
Cells were fed and grown on sterile microscopic slides in 100 mm diameter culture dishes in medium supplemented with twice daily additions of 0.25 mM sodium ascorbate (Sigma, St. Louis, MO) as described [29, 30] . After 9 days, the cells were rinsed and fixed for 10 rain in 100% methanol. Cells to be stained for fibronectin were grown in serum from which fibronectin was removed by passing it over an affinity column of immobilized gelatin [31] and were then stained according to the described procedures.
chyma (most intensely in subpial astrocytes) and the U251MG glioma cell line.
Silver stain for collagen
The Tibor pap silver stain for reticulin was performed as previously described [16, 32] . It is one of two fundamentally different histopathologic approaches to assess numbers and location of cells expressing extracellular matrix (ECM) in gliomas. This approach detects the histochemical capacity of glycosylated ECM fibrils to reduce and deposit silver. Other assays described below depend upon specific binding of fluorescent markers, providing opportunity for corroboration by different ECM assays. Classical 'reticulin' is often attributed to type III collagen, although other types of collagen or proteoglycans might contribute to material identified as collagen by silver staining [33, 34] .
Primary antisera
Rabbit anti-laminin and rabbit anti-type-IV collagen sera were donated by Drs. H. Kleinman and G. Martin [35, 36] . Affinity-purified rabbit and anti-laminin antibodies were prepared from whole antiserum by column chromatography as described previously [16] . The purified antibody was aliquoted and stored as stock solution at approximately 1 mg/ml. The purity of the antibody was assessed by SDS-gel electrophoresis and immunoelectrophoresis, and the specificity of the antibody was determined by immunodiffusion, ELISA, and immunoperoxidase staining reactions. Rabbit anti-GFAP was obtained from Dako.
The antibody and antiserum activities were tested in localizing components of human skin and brain tissue and cell line controls. Optimal dilutions of each primary antiserum were also determined at this time. Anti-laminin (1:20) , anti-fibronectin (1:50) and anti-type IV collagen (1:20) stained vessels, basement membranes and meninges. These antisera also stained LM, U138MG, and fibroblast cell lines. Anti-GFAP (1:50) stained brain paren-
Detection of extracellular matrix protein and GFAP with immunofluorescence
Methanol-fixed specimens were permeabilized with 0.3% Saponin in Dulbecco's PBS with 1 mM EGTA for 15 min to maximize staining of cytoplasmic epitopes. After 3 rinses in 0.01 M phosphatebuffered 0.85% saline (PBS), pH 7.2 (Difco, Detroit, MI), specimens were incubated with primary antiserum for 30 rain at room temperature. After 3 rinses in PBS, the specimens were stained with fluorescein-conjugated goat anti-IgG matched to the species of the primary antiserum (Cappel, Malvern, PA) diluted 1:100 in PBS for 30 min. Nuclei were counterstained with the DNA fluorochrome 4",6-diamidino-2-phenylindole as described below.
Control incubations included substitution of irrelevant antibody of the same species for the primary antibody [4, 16] . Fibronectin staining specificity was tested by substitution of directly labeled irrelevant primary antibody for the fluoresceinated anti-fibronectin and by absorption of anti-fibronectin with pure fibronectin (Collaborative Research, Lexington, MA) [31] . Collagenase digestion provided a further control on specificity of staining for reticulin and collagen type IV. Slides of cellular monolayers were divided with grease into two regions, one of which was incubated 1 day at 37 ~ C with purified collagenase (Form III, Advance Biofactures, Lynbrook, NY) in 0.025 M Tris buffer with 0.01 M calcium chloride. The other region on each slide was incubated in buffer alone. Tissue controls were done on additional sections from the same block.
Lectin-binding ligand fluorescence
Specimens were triple-rinsed with 0.005 M phosphate-buffered 0.15 M saline at a pH 7.2 (PBS) (Biofluids, Rockville, MD). Then 50 ~tg per ml PBS of fluorescein-conjugated Ulex europaeus agglutinin (Sigma, St. Louis, MO) was applied to these cells, which were not allowed to dry during staining. Specimens were incubated for 30 rain.
Lectin activity was tested in localizing components of brain tissue and cultured cells. Ulex europaeus agglutinin stained capillaries and the endothelial portions of larger vessels. LM, U138MG and fibroblast cells were negative.
fore did not interfere with evaluation of ECM components.
After immunofluorescent or lectin staining, the specimens were rinsed 3 times with PBS. They were counterstained with 20 gg/ml DAPI, rinsed in distilled water, and mounted under coverslips in Gelvatol.
Simultaneous detection of antigen with immunofluorescence and nuclear DNA with DAPI fluorochrome
To avoid any possibility of interference from RNA fluorescence and avoid cross-excitation with the primary ECM fluorochrome marker, the DNA fluorochrome 4',6-diamidino-2-phenylindole (DAPI, Monsanto, Indian Orchard, MA) was used to counterstain nuclei simultaneously stained for ECM. This facilitated quantitation of positive and negative cells. DAPI is a nuclear fluorochrome which stains DNA but not RNA [17] . It does not fuoresce when illuminated with 440-490 nm blue light used to excite fluorescein-labeled markers, and there- 
Quantitation of positive and negative cells
The experiments focused upon decisive markers of ECM components with unequivocally positive and negative regions in glioma tissue to facilitate standardization and comparison with these components in cells cultured from the same gliomas. Microscopic fields were selected by random movement of the specimen on the stage [37] . Positive and negative regions of tissue provided internal standardization of levels of fluorescence and silver staining. The lectin stain and antisera to ECM were chosen for this study on the basis of their ability to stain these positive regions brightly with low background fluorescence of negative regions. This produced preparations in which positive and negative cells would be unequivocally interpreted and counted. Cellular fluorescence was considered positive when it was distinctly brighter than background fluorescence of negative controls (brain parenchyma and U251 for fibronectin, brain parenchyma for laminin and type IV collagen, and brain vasculature and fibroblasts for GFAP). At least 10 microscopic fields per specimen were photographed with Kodak Tri-X film in a Zeiss fluorescence microscope with epi-illumination and transmitted incandescent light optics. For immunofluorescence, images of the same microscopic field were photographed first under 440490 nm excitation of fluorescein-labeled anti-ECM antibody or lectin (510 nm reflector and LP520 plus KP560 barrier filters), and second under 365 nm excitation of DAPI-stained nuclei (395 nm reflector). For subsequent enumeration, these images were superimposed to determine which nuclei were from positive cells and which were from negative cells.
Since cellular margins were impossible to distinguish with certainty in glioma tissue, cellular nuclei were counted in place of cells. For brevity these determinations are hereafter termed positive and negative 'cells'. On silver-stained preparations the nuclei of positive and negative cells were counted directly with transmitted light optics. The silver stain lacked sufficient cytoplasmic signal to count positive cells. Therefore, cells surrounded or covered by silver fibrils were considered positive. The exact criteria for counting cells positive with fluorescent markers were immunoreactive cytoplasm surrounding the shadow of a negative nucleus confirmed by superimposition of DAPI-stained images of the same field (for example, Figs 2B and 2D) . Fluorescent markers that stained cytoplasm sufficiently to reveal this nuclear shadow of absent protein precursor were selected to enable counting of positive cells. This excluded certain markers that failed to meet these criteria from the final data analysis (i.e., other collagen types and R i c i n u s c o m m uhis agglutinin) that did not produce sufficient cytoplasmic signal for counting.
More than 11,000 cells were counted for this study. A 2 x 2 contingency table was constructed with two rows for the total number of positive and At least 10 microscopic fields from each of three gliomas, b The average in vitro percentages reflect gliomas 1-3 only, since glioma 4 differed from these. Glioma 4 in vitro percentages are in brackets to the right, c Significant difference from in situ value (p < 0.05) by chi-squared analysis. ~ Indistinguishable from background fluorescence of negative controls (brain parenchyma & fibroblasts for Ulex europaeus).
negative cells and two columns for the in situ and in vitro cells. The tabulated data on each ECM component of each glioma were evaluated by Chisquared tests [38] . These data were expressed as percentages of positive cells (positive cells/total cells multiplied by 100) in Table 2 .
lnterphase cytogenetics by in situ hybridization
Cells grown on glass microscopic slides were fixed in 100% ethanol and air-dried. Specimens were incubated for 30 minutes in 2 • SSC pH 7.0 prewarmed to 37 ~ C. After dehydration and drying from ethanol, specimens were denatured in 70% Formamide/2 x SSC, at 70 ~ C for 2 min. After dehydration in graded ethanols at 4 ~ C, specimens were incubated with 15 ng of heat denatured digoxigenin labeled alpha satellite probes (Oncor) for the chromosomes of interest in 30 ~tl of hybridization mixture for 0.5-16 h. The hybridization mixture contained 65% formamide, 2 x SSC, 5% dextran sulfate, and 0.1 ~tg/~tl salmon sperm DNA [39] [40] [41] .
Specimens were washed with 40 ml of prewarmed 0.25X SSC pH 7.0 at 72 ~ C for 5 min, and in i x PBD for 2 min. They were then incubated with either fluorescein-or peroxidase-labeled anti-digoxigenin antibody at 37 ~ C for 5 min or 30 min, respectively, and washed 3 times in 1 x PBD at room temperature. Peroxidase-labeled specimens were developed with diaminobenzidine and counterstained with methyl green [41, 42] , dehydrated and mounted in Permount. Fluorescein-labeled specimens were counterstained with 0.3 ~tg/ml propidium iodide and mounted with Gelvatol or glycerol plus 1.4% di-azo-bicyclo-(2,2,2)-octane [43, 44] .
Results
All four neoplasms were astrocytic gliomas of high grade malignancy. Three were glioblastoma multiforme, grade IV by World Health Organization (WHO) criteria of diagnosis and grade [24] . The other (gliom~i number 3) was an anaplastic astrocytoma, grade III. By new WHO criteria this third glioma would also be considered a glioblastoma [5] .
The following features were evident in the tissues of all gliomas studied. ECM components (reticulin, type IV collagen, laminin, and fibronectin) localized within the walls of abnormal vascular proliferations, but not in parenchyma of glioma tissue excised in situ (Figs 1 and 2 , Table 1 ). Ulex europaeus bound endothelial cells (Fig. 3A) ; cells binding this marker were uniformly lost upon cultivation in vitro (Table 2 and Fig. 3B ). Changes in percentages of each marker that occurred during in vitro cultivation were calculated as the numerical ratio of percentage of positive cells in vitro divided by the percentage of positive cells in situ ( Table 3) . Three of these gliomas expressed each of the four extra-endothelial vascular ECM components on a greater percentage of cells in vitro than in situ (Figs I and 2, Table 3 ). The average increase in percentages of cells with reticulin, collagen, laminin, or fibronectin was between two-fold and four-fold. These same three gliomas retained few cells expressing GFAP upon cultivation (Tables  2 and 3 ). Gliomas I and 2 reevaluated in their tenth passage had lost all GFAP and retained all four ECM markers.
One glioma (number 4) produced a pattern of antigenic changes different than the other gliomas. Its retention of both parenchymal and specific vascular markers was striking. It retained GFAP and reticulin-positive cells, and it retained a smaller percentage of cells with fibronectin and laminin (Fig. 4 , Ta- ble 3). Type IV collagen-positive cells increased. To determine whether multiple cell populations might explain the mixture of vascular and parenchymal markers expressed by this glioma, it was cloned at limiting dilution. Clones expressed the markers of the parent line, but tended to show more ECM expression. Double labeling confirmed expression of vascular ECM and parenchymal markers in the same cell (Fig. 5) .
To determine which, if any, of these cells cultured from gliomas were neoplastic, in situ hybridization (ISH) for pericentromeric alpha satellite DNA sequences of chromosomes 7 and 10 was applied to fixed cell cultures. Gliomas frequently have more than the normal pair of chromosomes 7, and malignant gliomas often lose all or a part of one chromosome 10 [45] . Results indicate a profile of ISH signals typical of a malignant glioma in cells cultured from glioma 4 ( Table 4 ). Cells cultured from glioma 2 gave predominantly diploid ISH signal profiles similar to non-neoplastic control ceils. Remarkably, cells from glioma i gave a bizarre pattern of aneuploid signals (Table 4) . While clearly neoplastic, this pattern was not typical of a glioma. 
Discussion
All tumors, when studied immediately after biopsy, had essentially the same staining pattern, and the results of this study consisted of in vitro changes only. All ECM components of gliomas 1-3 increased upon culture. Some more than tripled their original percentages of positive cells in tissue. The gliomas that tended to lose GFAP upon cultivation generated a consistent direction of change toward the precise phenotype of non-endothelial cells from the walls of glioma vessels. This occurred in three gliomas among the four ECM components, GFAP and one lectin marker examined, a total of 18 individual observations. With each observation allowing change in the same or opposite direction as its counterpart, the possibility that this consistent pattern of phenotypic conversion resulted from random phenomena is less than 0.1%. The similarity of changes among these three cases provides evidence that they represent the most common form of transformation of ECM of gliomas. These results are most compatible with the possibility that mesenchymal cells in walls of their abnormal vascular proliferations outgrew the other cells cultured from these three gliomas. This would explain the loss of epidermal growth factor receptor gene amplification during glioma culture observed in other studies, since this gene is amplified in glioblastoma parenchyma rather than vascular proliferations [23, [46] [47] [48] . Interphase cytogenetic analysis indicates that these cells have either normal or neoplastic chromosomal signals.
While the possibility of cellular overgrowth producing changes in glioma phenotype has been previously proposed on the basis of descriptive evidence [15, 22, 49, 50] there have been minimal quantitative data to support this proposal. Many glioma cells in culture contain fibronectin, reticulin, type IV collagen, and laminin [16, 28, 29, 51, 52] . This contrasts with other studies that show relatively focal representation of these ECM components in glioma tissues [4, [6] [7] [8] [9] . Despite this suggestion of altered ECM expression from different studies, only fibronectin has been documented to increase on a cell percentage basis upon culture of individual gliomas [51] . The present study investigated all of these ECM components on a cell percentage basis in tissue and culture to determine whether such changes were occurring and their extent.
Highly intriguing is the single glioma in this study that, upon cultivation, did not convert to a cellular phenotype encountered in its tissue. A mixture of cells of different lineage does not explain this phenotype, since individual cells with markers of both glial and mesenchymal lineage were found after cloning and double labeling. There are more than one possible explanation for these changes resulting in the special array of gene products expressed by this glioma culture:
1. It may represent outgrowth of a rare type of glioma cell 'frozen' between expression of glial and expression of mesenchymal features. However, no cell of this phenotype was found in the tissue of this glioma. 2. Glioma parenchymal cells and cells within vascular proliferations may each produce an ECM. Glioma cells might then deposit this ECM at the vessel, possibly via their astrocytic foot processes that extend to meet the vascular adventitia. These foot processes might be analogous to the basal layer of an epithelial cell but located many microns away from their cell body. If this were the case, the ECM in this culture could originate in glioma parenchymal cells. 3. The components could be subject to complex alterations of gene expression which for unknown reasons favor expression of mesenchymal and/or vascular ECM antigens, but also allow continued expression of glial antigen.
Intraceltular GFAP can be modified to a degree in certain gliomas by changes in hormones, cellular density, configuration, or growth substrate [53] [54] [55] [56] [57] [58] [59] .
Since production of ECM proteins by glioma cultures has been recognized [60] , investigations of modulation of production of these ECM components have begun. Butyrate induces fibronectin and collagen gene expression in one established glioma cell line [61] . Of particular interest is the association of a human immunodeficiency virus regulatory protein with increased transcription of fibronectin and alpha I type I collagen promoters [62] . These studies pertain to the present observations by demonstrating that some coordinated expression of ECM components can be stimulated by exogenous agents. In the future, it would be interesting to determine whether these, or other agents, could produce the transformation encountered in this fourth glioma in the present study. These questions pertaining to mesenchymal drift are fundamental to a better understanding of gliomas which could provide therapeutic insights. For example, monoclonal antibody therapies targeting gliomas have had limited success, perhaps because they have aimed at a moving target of changing gene expression. If these changes are a manifestation of unlimited ability of the glioma cell to alter its 277 gene expression in response to the effects of exogenous agents, then the potential of glioma cells to escape therapy aimed at one phenotype by repeated phenotypic alterations is a serious concern. Changes that result from a limited number of different cell populations in gliomas, one of which outgrows the other, are more likely to be susceptible to targeted therapy like immunotherapy or growthfactor biomodulation, since each cell population can be individually managed.
